All Industries

Top Biotech Companies

5,081 Biotech companies, sorted by total funding raised.

Science.xyz

Clinical-stage medical technology company developing neural-engineering implants and platforms to...

Alameda, United States51–200Biotech, Medtech
Series C·$457.0M·Mar 2026
Crinetics Pharmaceuticals, Inc.

R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.

San Diego, United States11–50Biotech, Healthcare
Venture Round·$453.5M·Jan 2026
GalectoIPO

Clinical-stage biotech developing small-molecule therapeutics targeting galectin and other mechan...

Copenhagen, Denmark11–50Biotech, Drug Development
Series C·$446.9M·Nov 2025
X4 PharmaceuticalsIPO

Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a ran...

Boston, United States51–200Biotech, Drug Discovery
Series C·$446.8M·Oct 2025
Owkin

Owkin combines life-science and machine learning expertise to make drug development and clinical ...

San Francisco, United States201–500Artificial Intelligence, Biotech
Corporate Round·$445.2M·Jan 2023
Cue HealthClosed

Biotech company empowering personalized, proactive healthcare through at-home diagnostic testing.

San Diego, United States201–500Biotech, Healthcare
Series D·$440.0M·May 2021
Helix

Population genomics and viral surveillance company enabling health systems and public health orga...

San Mateo, United States201–500Biotech, Diagnostics
Series C·$435.0M·Jun 2021
AvalynIPO

Developing inhaled therapies to treat people with severe respiratory disease.

Boston, United States11–50Biotech, Healthcare
Series D·$434.5M·Jul 2025
Ollin Biosciences

Biotechnology company developing novel therapeutics.

Austin, United States11–50Biotech, Healthcare
Series B·$430.0M·Jun 2026
Verve TherapeuticsAcquired

Develops one-time in vivo gene-editing medicines to prevent and treat atherosclerotic cardiovascu...

Boston, United States201–500Biotech, Drug Discovery
Series C·$428.5M·Oct 2024
Mineralys TherapeuticsIPO

Clinical-stage biopharmaceutical company developing treatments for cardiorenal metabolic syndrome.

Radnor, United States11–50Biotech, Healthcare
Corporate Round·$428.0M·Jun 2026
AdvanCell

Biotech company developing next-generation cell and gene therapies for cancer.

Sydney, Australia11–50Biotech, Healthcare
Venture Round·$427.0M·Jul 2026
Areteia TherapeuticsClosed

Clinical-stage biotechnology developing an oral eosinophil-maturation inhibitor (dexpramipexole) ...

Chapel Hill, United States11–50Biotech, Life Sciences
Series A·$425.0M·Feb 2024
Allogene TherapeuticsIPO

Clinical-stage biotechnology company developing allogeneic CAR T cell therapies for blood cancers...

South San Francisco, United States51–200Biotech, Healthcare
Series A·$420.0M·Apr 2018
Scorpion Therapeutics

Targeted oncology therapies

Boston, United States51–200Biotech, Healthcare
Series C·$420.0M·Jul 2024
MT
Morphic Therapeutic

Biopharmaceutical company developing oral integrin therapies for immunological, fibrotic, neoplas...

Waltham, United States51–200Biotech, Healthcare
Series C·$414.0M·May 2023
Benchling

Unlocking the power of biotech with modern software for modern science

San Francisco, United States501–1000Biotech, SaaS
Series G+·$412.0M·Nov 2021
Enzene Biosciences

Global biologics CDMO specializing in biosimilars development, manufacturing, and continuous biop...

IndiaBiotech, Contract Manufacturing
Private Equity·$412.0M·Dec 2025
Verdiva Bio

Verdiva Bio is a clinical-stage biopharmaceutical company focused on developing innovative therap...

London, United Kingdom11–50Life Sciences, Biotech
Series A·$411.0M·Jan 2025
CStone PharmaceuticalsIPO

Innovation-driven biopharmaceutical company focused on immuno-oncology and molecularly targeted t...

Suzhou, China201–500Biotech, Healthcare
Series B·$410.0M·May 2018
Sonoma Biotherapeutics

Develops engineered regulatory T cell therapies to restore immune balance and treat autoimmune an...

Seattle, United States51–200Biotech, Life Sciences
Corporate Round·$410.0M·Sep 2024
Abcuro

Abcuro is a clinical-stage company developing Ulviprubart, a FIC anti-KLRG1 antibody in Ph2/3 piv...

Newton, United States51–200Biotech, Healthcare
Series C·$407.3M·Feb 2025
BillionToOneIPO

The genetic testing platform detecting and measuring disease.

Menlo Park, United States201–500Biotech, Diagnostics
Venture Round·$406.0M·Mar 2026
Dianthus TherapeuticsIPO

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation comple...

New York, United States11–50Biotech, Healthcare
Venture Round·$400.0M·Sep 2023
Upstream BioIPO

Clinical-stage biotechnology company developing treatments for inflammatory diseases, with an ini...

Waltham, United States51–200Biotech, Healthcare
Series B·$400.0M·Jun 2023